We report a case of an HIV-infected patient who was successfully treated with ritonavir/lopinavir (r/LPV) mono-therapy for several years. He presented with neurological symptoms and high HIV RNA levels in cerebrospinal fluid (CSF). Sequencing of the HIV from the CSF revealed mutations in the protease gene refecting resistance against most protease inhibitors, that is, lopinavir and ritonavir. His regimen was switched and after 2 months the HIV RNA viral load was again undetectable in both plasma as well as in CSF. Monotherapy with r/LPV may not be sufficient to fully suppress viral replication in the central nervous system in all individuals and may lead to compar-timentalization and the selection of resistant mutations of HIV in the central nervous system.
References
1.
SolasC., LafeuilladeA., HalfonP., ChadapaudS., HittingerG., LacarelleB.Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother2003; 47: 238–243.
2.
LetendreS., Marquie-BeckJ., CapparelliE.Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol2008; 65: 65–70.
3.
MocroftA., DevereuxH., Kinloch-de-LoesS.Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. AIDS2000; 14: 1545–1552.
4.
EdénA., FuchsD., HagbergL.HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis2010; 202: 1819–1825.
5.
CanestriA., LescureF.X., JaureguiberryS.Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis2010; 50: 773–778.
6.
CapparelliE.V., HollandD., OkamotoC.Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS2005; 19: 949–952.
7.
BestettiA., PresiS., PierottiC.Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. J Neurovirol2004; 10Suppl 1: 52–57.
8.
LetendreS.L., Brande van denG., HermesA.Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin Infect Dis2007; 45: 1511–1517.
9.
GarveyL.J., EverittA., WinstonA., MackieN.E., BenzieA.Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartment. AIDS2009; 23: 1443–1444.
10.
SpudichS., LolloN., LieglerT., DeeksS.G., PriceR.W.Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis2006; 194: 1686–1696.
11.
van LelyveldS.F., NijhuisM., BaatzF.Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid. Clin Infect Dis2010; 50: 387–390.
12.
CliffordD.B.Viral escape in cerebrospinal fluid – an Achilles heel of HIV therapy?J Infect Dis2010; 202: 1768–1769.
13.
de TruchisP., MathezD., AbeE.Cerebrospinal fluid HIV-1 virological escape with lymphocytic meningitis under lopinavir/ritonavir monotherapy. AIDS2010; 24: 1235–1236.
14.
GutmannC., CusiniA., GunthardH.F.Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS2010; 24: 2347–2354.
15.
SmitT.K., BrewB.J., TourtellotteW., MorgelloS., GelmanB.B., SaksenaN.K.Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol2004; 78: 10133–10148.
